Skip to main content
Journal cover image

Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial.

Publication ,  Journal Article
Kamble, S; Weinfurt, KP; Schulman, KA; Reed, SD
Published in: Med Decis Making
February 2013

BACKGROUND: Sensor-augmented pump therapy (SAPT) leads to lower glycated hemoglobin levels than multiple daily injections of insulin (MDI) in patients with type 1 diabetes. Patient time and costs associated with SAPT are not known. OBJECTIVE: We compared time spent on diabetes-related care, changes in time, and associated patient time costs between patients randomly assigned to SAPT or MDI. DESIGN, SETTING, AND PARTICIPANTS. During a 52-week clinical trial, participants aged 7 to 70 years (n = 483) reported total time per week spent on diabetes-related care. MEASUREMENTS: Patient time, including comparisons during pump initiation, 52-week patient time costs, and changes in weekly time estimates after pump initiation. RESULTS: At baseline, patients in the MDI group reported spending an average of 4.0 hours per week on diabetes-related care. During the pump initiation period (weeks 1-7), SAPT patients spent 1.9 hours more per week than MDI patients (95% confidence interval [CI], 1.2-2.6). After the initiation period (weeks 8-52), SAPT patients spent 1 hour more per week (95% CI, 0.4-1.7) than MDI patients (i.e., 4.4 v. 3.4 hours); patients in both groups spent progressively less time on diabetes-related care by 1.2 minutes per week (95% CI, -1.7 to -0.7). Overall, mean time costs per person were $4600 with the SAPT group and $3523 with the MDI group (difference, $1077; 95% CI, $491-$1638). LIMITATIONS: Time spent on specific activities was not collected, and the estimates do not explicitly account for caregiver time associated with diabetes care activities. CONCLUSIONS: Patients receiving SAPT v. MDI spent approximately 2 hours more per week on diabetes-related care during pump initiation and 1 hour more per week thereafter, resulting in higher patient time costs.

Duke Scholars

Published In

Med Decis Making

DOI

EISSN

1552-681X

Publication Date

February 2013

Volume

33

Issue

2

Start / End Page

215 / 224

Location

United States

Related Subject Headings

  • Young Adult
  • Time and Motion Studies
  • Middle Aged
  • Insulin
  • Infusion Pumps
  • Humans
  • Health Policy & Services
  • Health Care Costs
  • Diabetes Mellitus, Type 1
  • Child
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kamble, S., Weinfurt, K. P., Schulman, K. A., & Reed, S. D. (2013). Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial. Med Decis Making, 33(2), 215–224. https://doi.org/10.1177/0272989X12464824
Kamble, Shital, Kevin P. Weinfurt, Kevin A. Schulman, and Shelby D. Reed. “Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial.Med Decis Making 33, no. 2 (February 2013): 215–24. https://doi.org/10.1177/0272989X12464824.
Kamble, Shital, et al. “Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial.Med Decis Making, vol. 33, no. 2, Feb. 2013, pp. 215–24. Pubmed, doi:10.1177/0272989X12464824.
Journal cover image

Published In

Med Decis Making

DOI

EISSN

1552-681X

Publication Date

February 2013

Volume

33

Issue

2

Start / End Page

215 / 224

Location

United States

Related Subject Headings

  • Young Adult
  • Time and Motion Studies
  • Middle Aged
  • Insulin
  • Infusion Pumps
  • Humans
  • Health Policy & Services
  • Health Care Costs
  • Diabetes Mellitus, Type 1
  • Child